Anti-proliferative effect of a triazole derivative (ST1959) on LNCaP human prostate cancer cells through down-regulation of cyclin and androgen receptor expression

Prostate

Volumn 71, Issue 1, 2011, Pages 32-41

  Loiarro, Maria ^a,b   Campo, Silvia ^c   Arseni, Brunilde ^c   Rossi, Stefania ^c   D'Alessio, Valeria ^c   De Santis, Rita ^c   Sette, Claudio ^a,b   Ruggiero, Vito ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c Sigma Tau SpA   (Italy)

Author keywords

androgen receptor; cell cycle; cyclins; prostate cancer; ST1959; triazoles

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; CYCLIN A; CYCLIN B; CYCLIN D1; ST 1959; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR DOWN REGULATION;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLINS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRIAZOLES;

EID: 78649551299     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21219     Document Type: Article

References (35)

1. Galliani G, Assandri A, Gallico L, Luzzani F, Oldani C, Omodei-Salè A, Soffientini A, Lancini G,. A new non-hormonal pregnancy-Terminating agent. Contraception 1981; 23: 163-180.
2. Mistrello G, Galliani G, Assandri A, Filippeschi S, Bassi L,. Immunological profile of DL111-IT, a new immunosuppressant agent. Immunopharmacology 1985; 10: 163-169.
3. Ruggiero V, Albertoni C, Rosi A, Leoni B, Carminati P, De Santis R,. Efficacy of ST1959 in murine models of autoimmunity and insights into its peculiar immunomodulatory profile. Int J Immunother 2003; 19: 1-10.
4. Stasi MA, Ruggiero V, Ursillo A, Taurelli R, Aglianò M, Weber E, Lorenzoni P, Sorrentino V, Pacifici L, Carminati P,. Ameliorating effects of the immunomodulator 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole in an experimental model of colitis in the rat. Eur J Pharmacol 2004; 494: 263-272.
5. Campo S, Arseni B, Rossi S, D'Alessio V, Lu R, Ngoje J, Ahl PL, Bonitz S, Mannino R, Di Mitri D, Battistini L, Carminati P, De Santis R, Ruggiero V,. Efficacy of a nanocochleate-encapsulated 3,5-diaryl-s-triazole derivative in a murine model of graft-versus-host disease. Transplantation 2008; 86: 171-175.
6. D'Alessio V, Campo S, Arseni B, Rossi S, Ruggiero V, Carminati P, De Santis R,. Study of ERK1/2 pathway in a model of ST1959 inhibition of eotaxin production and cell proliferation. Minerva Biotecnol 2004; 16: 5.
7. Campo S, Arseni B, Rossi S, Ruggiero V, Carminati P, De Santis R,. Effect of ST1959 on "in vitro" chemokine production and activity in animal models of experimental inflammation. Minerva Biotecnol 2004; 16: 4.
8. Lindstedt R, Ruggiero V, D'Alessio V, Manganello S, Petronzelli F, Stasi MA, Vendetti S, Assandri A, Carminati P, De Santis R,. The immunosuppressor ST1959-a 3,5-diaryl-s-triazole derivative-inhibits T cell activation by reducing NF-AT nuclear residency. Int J Immunopathol Pharmacol 2009; 22: 29-42.
9. De Santis R, Angelini DF, Cencioni MT, Diamantini A, Amadio S, Ruggiero V, Carminati P, Volontè C, Borsellino G, Battistini L,. ST1959 is an effective suppressor of antigen specific gamma delta T cell responses in healthy and multiple sclerosis individuals. J Neuroimmunol 2004; 154: 209.
10. Burattini S, Luchetti F, Battistelli M, della Felice M, Papa S, Piersanti G, Tarzia G, Falcieri E,. 5-(2-Ethyl-phenyl)-3-(3-methoxy-phenyl)-1H-[1,2,4] triazole (DL-111-IT) and related compounds induce apoptotic patterns in cultures of human tumor cell lines. J Biol Regul Homeost Agents 2003; 17: 348-357.
11. Yang B, He QJ, Zhu DY, Lou YJ, Fang RY,. Antiproliferative activity of contragestazol (DL111-IT) in murine and human tumor models in vitro and in vivo. Cancer Chemother Pharmacol 2006; 57: 268-273.
12. He QJ, Yang B, Lou YJ, Fang RY,. Contragestol (DL111-IT) inhibits proliferation of human androgen-independent prostate cancer cell line PC3 in vitro and in vivo. Asian J Androl 2005; 7: 389-393.
13. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics. CA Cancer J Clin 2009; 59: 225-249.
14. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B,. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986; 76: 45-48.
15. Thompson IM, Coltman CA, Brawley OW, Ryan A,. Chemoprevention of prostate cancer. Semin Urol 1995; 13: 122-129.
16. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ,. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990; 50: 5382-5386.
17. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD,. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999; 18: 7389-7394.
18. Zhang J, Chen Y, Xin XL, Li QN, Li M, Lin LP, Geng MY, Ding J,. Oligomannurarate sulfate blocks tumor growth by inhibiting NF-kappaB activation. Acta Pharmacol Sin 2010; 31: 375-381.
19. Carroll AG, Voeller HJ, Sugars L, Gelmann EP,. p53 oncogene mutations in three human prostate cancer cell lines. Prostate 1993; 23: 123-134.
20. Trapman J, Brinkmann AO,. The androgen receptor in prostate cancer. Pathol Res Pract 1996; 192: 752-760.
21. Trapman J, Cleutjens KB,. Androgen-regulated gene expression in prostate cancer. Semin Cancer Biol 1997; 8: 29-36.
22. Taplin ME, Balk SP,. Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004; 91: 483-490.
23. Lu S, Tsai SY, Tsai MJ,. Regulation of androgen-dependent prostatic cancer cell growth: Androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res 1997; 57: 4511-4516.
24. Singh RP, Agarwal R,. Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer 2006; 13: 751-778.
25. Han EK, Lim JT, Arber N, Rubin MA, Xing WQ, Weinstein IB,. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate 1998; 35: 95-101.
26. Schwartz GK, Shah MA,. Targeting the cell cycle: A new approach to cancer therapy. J Clin Oncol 2005; 23: 9408-9421.
27. Chen Y, Martinez LA, LaCava M, Coghlan L, Conti CJ,. Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1. Oncogene 1998; 16: 1913-1920.
28. He Y, Franco OE, Jiang M, Williams K, Love HD, Coleman IM, Nelson PS, Hayward SW,. Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression. Cancer Res 2007; 67: 8188-8197.
29. Suzuki H, Graziano DF, McKolanis J, Finn OJ,. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res 2005; 11: 1521-1526.
30. Kallakury BV, Sheehan CE, Rhee SJ, Fisher HA, Kaufman RP Jr, Rifkin MD, Ross JS,. The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: A comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2. Cancer 1999; 85: 1569-1576.
31. Porter LA, Donoghue DJ,. Cyclin B1 and CDK1: Nuclear localization and upstream regulators. Prog Cell Cycle Res 2003; 5: 335-347.
32. Egloff AM, Vella LA, Finn OJ,. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res 2006; 66: 6-9.
33. Shen M, Feng Y, Gao C, Tao D, Hu J, Reed E, Li QQ, Gong J,. Detection of cyclin B1 expression in G1-phase cancer cell lines and cancer tissues by postsorting Western blot analysis. Cancer Res 2004; 64: 1607-1610.
34. Gregory CW, Johnson RT Jr, Presnell SC, Mohler JL, French FS,. Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft. J Androl 2001; 22: 537-548.
35. Lu J, Zhang J, Zeng Y,. Androgen receptors and effects of sex hormones on growth of a human ovarian carcinoma cell line. Zhonghua Fu Chan Ke Za Zhi 1995; 30: 360-362.